Trials / Active Not Recruiting
Active Not RecruitingNCT05533463
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Phase I Study to Evaluate the Safety ,Tolerability, and Pharmacokinetics of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose \[RP2D\]) within investigated subject population groups
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-4642 | HRS-4642 will be administrated per dose level in which the patients are assigned. |
Timeline
- Start date
- 2022-09-21
- Primary completion
- 2024-06-25
- Completion
- 2025-12-30
- First posted
- 2022-09-09
- Last updated
- 2025-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05533463. Inclusion in this directory is not an endorsement.